新型细胞免疫治疗相关心血管毒性
综述探讨嵌合抗原受体T细胞(CAR-T)与双特异性T细胞衔接器(BTE)等T细胞导向疗法及肿瘤浸润淋巴细胞治疗相关心血管毒性,汇总报告发生率、危险因素、机制与管理策略,重点阐述心律失常、心力衰竭、心肌炎、出血等事件及细胞因子释放综合征与心脏毒性的关系,并指出关键未解问题与未来研究方向。
要点
- CAR-T与BTE疗法可能伴发高发生率严重心血管毒性,包括房颤、心衰、室性心律失常等。
- 心血管事件是此类治疗后长期生存的主要限制因素。
- 综述聚焦心律失常、心衰、心肌炎、出血等事件的发生率、危险因素、机制与管理策略。
核心结论
- 新型T细胞导向疗法可能伴发高发生率严重心血管毒性,是长期生存的主要限制因素,其发生率、危险因素、机制与管理策略尚待进一步明确。
研究设计与样本
- 综述,检索并汇总CAR-T、BTE及肿瘤浸润淋巴细胞相关心血管毒性的现有证据。
主要发现
- 新兴数据提示CAR-T与BTE等疗法可能伴发高发生率严重心血管毒性,包括房颤、心衰、室性心律失常及其他心血管毒性。
- 心血管事件是此类治疗后长期生存的主要限制因素。
- 综述重点阐述CAR-T与BTE疗法与心律失常、心衰、心肌炎、出血及其他主要心血管事件的关系。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the past decade, T-cell-directed therapies, including chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager (BTE) therapies, have reshaped the treatment of an expanding number of hematologic malignancies, whereas tumor-infiltrating lymphocytes, a recently approved cellular therapy, targets solid tumor malignancies. Emerging data suggest that these therapies may be associated with a high incidence of serious cardiovascular toxicities, including atrial fibrillation, heart failure, ventricular arrhythmias, and other cardiovascular toxicities. The development of these events is a major limitation to long-term survival after these treatments. This review examines the current state of evidence, including reported incidence rates, risk factors, mechanisms, and management strategies of cardiovascular toxicities after treatment with these novel therapies. We specifically focus on CAR-T and BTE therapies and their relation to arrhythmia, heart failure, myocarditis, bleeding, and other major cardiovascular events. Beyond the relationship between cytokine release syndrome and cardiotoxicity, we describe other potential mechanisms and highlight key unanswered questions and future directions of research.
引用
- Munir M, Sayed A, Addison D, et al. Cardiovascular toxicities associated with novel cellular immune therapies. Blood Adv. 2024. PMID: 39418640. doi:10.1182/bloodadvances.2024013849
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。